{"classes":[{"categories":[{"measurements":[{"comment":"NA indicates that upper limit of CI was not estimable due to insufficient number of participants with events at DCO date.","groupId":"OG000","lowerLimit":"25.791","upperLimit":"NA","value":"29.04"},{"comment":"NA indicates that median and upper limit of CI was not estimable due to insufficient number of participants with events at DCO date.","groupId":"OG001","lowerLimit":"22.177","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"188"}],"units":"Participants"}],"description":"DOR: Time from the date of first response to the date of first occurrence of progressive disease (PD) determined by IRC or death from any cause, whichever occurred first.DOR was determined only for participants who achieved a response (PR or better).If PD/death not observed, participant was censored at date of last valid disease assessment performed prior to initiating further anti-myeloma treatment or analysis cut-off date, whichever occurred first. As per IMWG criteria: PD: increase of \\>=25% from lowest confirmed value in any 1 of following: serum M-protein (absolute increase\\>=0.5 gram/deciliter\\[g/dL\\]),serum M-protein increase\\>=1g/dL if lowest M-component \\>=5g/dL, urine M-component (absolute increase \\>=200mg/24h), appearance of new lesion(s),\\>=50% increase from nadir in SPD of \\>1 lesion or \\>=50% increase in longest diameter of a previous lesion \\>1 centimeter (cm) in short axis. PR: as defined in OM1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion QW (i.e. on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 10 mg/kg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG000","title":"Isa-IV + Pd"},{"description":"Participants received isatuximab 1400 mg SC injection administered via an OBDS which is an investigational device injector QW (i.e on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 1400 mg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG001","title":"Isa-SC + Pd"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all randomized population. Only responders (participants who achieved a response of PR or better subsequently confirmed based on disease assessment by IRC) were included in the analysis.","reportingStatus":"POSTED","timeFrame":"From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}